Threshold Pharmaceuticals has released the results of its clinical trial of TH-302 for patients with advanced solid tumours and said the data supports the need for an additional study.
The clinical trial was a Phase I/II, three arm, multicentre dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine, docetaxel or pemetrexed, the company said.
Go deeper with GlobalData
Threshold Pharmaceuticals managing director John Hurd said while limited in number, the results in patients with first-line pancreatic cancer are notable as compared to historical standards.
“Historically, the response rates in first-line pancreatic cancer with gemcitabine have been less than 10%. We believe that the safety and activity data supports an additional study of TH-302 in combination with full-dose gemcitabine to determine if TH-302 adds clinical benefit to patients fighting pancreatic cancer,” Hurd said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
